SEC Tracker
Get the app
SRZN · XBRL financial data

Surrozen financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (SRZN's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue———010,6553,477
Research and development25,68440,17737,01327,23021,13229,365
General and administrative7,12314,21419,82615,79815,06216,204
Total operating expenses32,80754,39156,83945,78036,19445,569
Operating income (loss)(32,807)(54,391)(44,339)(45,780)(25,539)(42,092)
Interest income91727812,3401,6933,020
Other income (expense)0(329)7,554398(19,321)(26,312)
Income tax expense (benefit)000000
Net income (loss)(32,716)(54,648)(36,004)(43,042)(63,564)(242,026)
Earnings per share, basic USD per share—(2.21)(1.04)(21.33)(21.67)(32.37)
Earnings per share, diluted USD per share—(2.21)(1.04)(21.33)(21.67)(32.37)
Weighted average shares, basic thousands of shares—2535237
Weighted average shares, diluted thousands of shares—2535237

Balance sheet

CSV

Fiscal years (SRZN's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents98733,09124,69036,04334,56589,245
Short-term investments14,200—————
Marketable securities14,20068,76051,1480——
Marketable securities, non-current021,6550———
Accounts receivable—01,9782,1522,0390
Prepaid and other current assets1,0423,3383,4892,9371,8262,106
Total current assets1,778105,18981,30541,13238,93291,559
Property and equipment, net5,8364,7943,6301,969562433
Right-of-use asset5,5564,5823,2681,8897,8016,000
Total assets93,775137,17489,43546,08048,46798,726
Accounts payable1,7762,718658525306728
Accrued liabilities3,3948,6626,8484,1265,1807,912
Total current liabilities7,27813,5739,7327,1487,3159,930
Lease liability, non-current7,4895,6003,3768826,6405,349
Total liabilities6,91427,47413,4348,14569,847286,488
Accumulated deficit(2,122)(142,649)(178,653)(221,695)(285,259)(527,285)
Total stockholders' equity5,000109,70076,00137,935(21,380)(187,762)
Total liabilities and equity93,775137,17489,43546,08048,46798,726
Common shares outstanding (cover page) thousands of shares18,25735,12730,0793,1993,28111,487

Cash flows

CSV

Fiscal years (SRZN's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(32,716)(54,648)(36,004)(43,042)(63,564)(242,026)
Stock-based compensation6352,3164,5174,3724,1143,835
Net cash from operating activities(29,099)(48,813)(44,145)(40,363)(17,628)(30,244)
Purchases of property and equipment8741,26972839826128
Net cash from investing activities(15,075)(77,708)38,30951,723(26)(128)
Proceeds from issuing common stock0124,2200016,04374,702
Share repurchases—02,6070——
Net cash from financing activities50,052124,630(2,565)27616,17685,052
Net change in cash5,878(1,891)(8,401)11,636(1,478)54,680

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Surrozen102,0395,000(7,415)*11.8M13.8 quarters 10-QJun 30, 2026
Sutro Biopharma54,3359,839(38,290)*16.6M4.3 quarters 10-QJun 30, 2026
PDS Biotechnology5,596not reported(2,793)*56.0M2.0 quarters 10-QJun 30, 2026
iBio56,3950*(6,228)*64.3M14.1 quarters 10-KJun 30, 2026
Medicinova25,416458(1,920)*49.2M13.2 quarters 10-QJun 30, 2026
Lifevantage14,92042,377*4,767*12.5M— 10-KJun 30, 2026
Veru23,880not reported(5,467)*17.1M4.4 quarters 10-QJun 30, 2026
Whitehawk Therapeutics85,2340(14,529)*57.0M13.1 quarters 10-QJun 30, 2026
Avalo Therapeutics85,382not reported(19,988)*53.6M20.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.